title: Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
abstract: [(18)F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is increasingly used for response assessment in diffuse large B-cell lymphoma (DLBCL). A positive interim FDG-PET was shown to be associated with an unfavorable outcome in high-grade non-Hodgkin's lymphomas. For positive interim FDG-PET patients, the question of increasing the intensity of treatment using high-dose chemotherapy followed by auto-SCT (HDC-ASCT) remains unanswered. We retrospectively analyzed the prognostic value of FDG-PET in 42 DLBCL patients who were systematically evaluated at time of diagnosis, before and after HDC-ASCT. Of note, HDC-ASCT was part of the initial treatment strategy, while FDG-PET results did not influence the treatment approach. Results and outcome were analyzed according to FDG-PET results before and after HDC-ASCT. Patients were classified into three groups according to FDG-PET results before and after HDC-ASCT: those who were negative before and after (-/-; n=25), positive before and negative after (+/-; n=9) or positive before and after (+/+; n=8). The median follow-up was 34.5 (range, 19-74) months. The median EFS was significantly lower for the +/+ group (27.4 months) as compared with other groups (median not reached; P=0.0001). More importantly, there was no difference in term of EFS between the -/- group compared with the +/- group. These results suggest that HDC-ASCT can significantly improve the bad prognosis, otherwise indicated by a positive interim FDG-PET.
authors.affiliation: Centre Hospitalier Universitaire de Nantes, Service d'Hématologie Clinique, Nantes, France.
authors.forename: V
authors.initials: V
authors.lastname: Roland
authors.forename: C
authors.initials: C
authors.lastname: Bodet-Milin
authors.forename: A
authors.initials: A
authors.lastname: Moreau
authors.forename: T
authors.initials: T
authors.lastname: Gastinne
authors.forename: B
authors.initials: B
authors.lastname: Mahé
authors.forename: V
authors.initials: V
authors.lastname: Dubruille
authors.forename: H
authors.initials: H
authors.lastname: Maisonneuve
authors.forename: N
authors.initials: N
authors.lastname: Juge-Morineau
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: H
authors.initials: H
authors.lastname: Jardel
authors.forename: L
authors.initials: L
authors.lastname: Planche
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: J-L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: F
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18